CORRECTED-CSL signs licensing deal with Eli Lilly for clazakizumab
ReutersFeb 18, 2026 1:24 AM
Feb 18 (Reuters) - Australia's CSL CSL.AX said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co LLY.N, granting it certain rights to develop and commercialise clazakizumab, an antibody aimed at preventing heart-related illness and death in people with end‑stage kidney disease.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
When Investing in Virtual Land or the Metaverse, Why Meta Is the Best Choice?
TradingKey - Interest in digital real estate peaked in the early 2020s, but now that interest in it has cooled, and prices have dropped, the practical questions start for investors. If investors want exposure to virtual land or the Metaverse, how should investors approach it? For virtual land investTradingKey
4 hours ago
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?TradingKey
Fri, Feb 13
This $1 Trillion AI Stock Is Getting Ready for 2026: Is Meta a Good Buy?
When ads and commerce are factored in, Meta is building a long-term platform—in Augmented Reality and smart glasses — to get us closer to the future of AI. This device hardware business is less profitable than ads right now, but it could grow the company’s ecosystem and open up new ways for it to maTradingKey
Thu, Feb 12
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.TradingKey
Thu, Feb 12
